Sweden· SE-20251119000038
Exemestan Abacus Medicine 25 mg Filmdragerad tablett
A exemestane product, registered in Sweden by Abacus Medicine A/S. The same ATC class is registered in 17 of our 19 countries.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
Where it is registered
Exemestane is registered in 17 of 19 countries.
Countries holding a registration under ATC L02BG06 (exemestane), each read from that country’s own register.
- This record: Sweden, from Swedish Medical Products Agency (Sweden)
- 10 of them publish a price we can compare per daily dose
Exemestane · ATC L02BG06
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of exemestane costs, country by country.
Normalised to the WHO defined daily dose (25 mg), the median price runs from $1.43 in France to $3.32 in Switzerland — a ×2.3 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Exemestane · price per daily dose (25 mg)
USD · FX 28 Sept 2026
- CH Switzerland$3.32
- IT Italy$2.46
- FR France$1.43
The record
At a glance
Swedish Medical Products Agency (Sweden)- Manufacturer
- Abacus Medicine A/S
- Country
- Sweden (SE)
- ATC code
- L02BG06
- ATC class
- Exemestane
- Defined daily dose
- 25 mg, O
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20251119000038
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
236 interactions on record for exemestane.
Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Exemestane · interactions on record
236 records
- 1 severe
- 83 moderate
- 152 info
Most severe, free to view
- ThalidomideL04AX02severe
- TroglitazoneA10BG01moderate
- SulfinpyrazonB01AC12moderate
- FostamatinibB02BX09moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under L02BG06
Exemestane, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fba2ecf2-28de-4153-be2b-312a67a272e5 GET /v1/drugs/fba2ecf2-28de-4153-be2b-312a67a272e5?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"PL"
],
"se_npl_id": "20251119000038",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20251119000038",
"product_doc_link": "https://docetp.mpa.se/LMF/Exemestan%20Abacus%20Medicine%2025%20mg%20film-coated%20tablet%20DE%20PL_09001bee84f60a53.pdf"
}See everything about exemestane.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.